Literature DB >> 23455589

Luteal serum BDNF and HSP70 levels in women with premenstrual dysphoric disorder.

E Oral1, H Ozcan, T S Kirkan, S Askin, M Gulec, N Aydin.   

Abstract

Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome characterized by psychological and somatic symptoms commencing in the luteal phase of the menstrual cycle and concludes with menstrual bleeding. PMDD affects 3-8 % of premenopausal women and represents a significant public health problem especially in young women. Decreased brain-derived neurotrophic factor (BDNF) levels are associated with several mental disorders. Heat-shock protein-70 (HSP70) is an important member of the molecular chaperone system, which provides a molecular defense against proteotoxic stress. We hypothesized that there would be changed levels of BDNF and HSP70 in women with PMDD compared with non-symptomatic women, reflecting impaired and/or activated stress-related responses involved in the underlying pathogenesis of PMDD. Female medical students were screened, and 24 women without premenstrual symptoms and 25 women with PMDD were enrolled in the study. Psychiatric evaluation and the Daily Record of Severity of Problems-Short Form were used for two consecutive menstrual cycles to diagnose PMDD. Serum BDNF and HSP70 levels were assessed in the third luteal phase. Participants with PMDD had significantly higher serum BDNF and HSP70 levels compared with controls, and there was a significant positive correlation between serum BDNF and HSP70 levels. Increased HSP70 levels may reflect cellular distress in PMDD. Increased serum BDNF levels in the luteal phase in subjects with PMDD may reflect a compensation process, which results in subsequent improvement of PMDD-associated depressive symptoms in the follicular phase. Thus, increased serum BDNF levels may be indicative of a compensating capacity in PMDD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23455589     DOI: 10.1007/s00406-013-0398-z

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  104 in total

Review 1.  Glial cells and chronic pain.

Authors:  Romain-Daniel Gosselin; Marc R Suter; Ru-Rong Ji; Isabelle Decosterd
Journal:  Neuroscientist       Date:  2010-06-25       Impact factor: 7.519

2.  Short-term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat.

Authors:  M Gulinello; Q H Gong; X Li; S S Smith
Journal:  Brain Res       Date:  2001-08-10       Impact factor: 3.252

3.  Brain-derived neurotrophic factor plasma variation during the different phases of the menstrual cycle in women with premenstrual syndrome.

Authors:  Alessandra Cubeddu; Fiorella Bucci; Andrea Giannini; Marinella Russo; Diana Daino; Natalia Russo; Sara Merlini; Nicola Pluchino; Valeria Valentino; Elena Casarosa; Stefano Luisi; Andrea Riccardo Genazzani
Journal:  Psychoneuroendocrinology       Date:  2010-10-08       Impact factor: 4.905

4.  Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects.

Authors:  I Sundström; A Andersson; S Nyberg; D Ashbrook; R H Purdy; T Bäckström
Journal:  Neuroendocrinology       Date:  1998-02       Impact factor: 4.914

Review 5.  Depression and Alzheimer's disease: neurobiological links and common pharmacological targets.

Authors:  Filippo Caraci; Agata Copani; Ferdinando Nicoletti; Filippo Drago
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

6.  Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants.

Authors:  Hwa-Young Lee; Yong-Ku Kim
Journal:  Neuropsychobiology       Date:  2008-08-05       Impact factor: 2.328

Review 7.  Neurotrophins and neurodegeneration.

Authors:  D Dawbarn; S J Allen
Journal:  Neuropathol Appl Neurobiol       Date:  2003-06       Impact factor: 8.090

8.  Proton magnetic resonance spectroscopy measurement of brain glutamate levels in premenstrual dysphoric disorder.

Authors:  Neha Arun Batra; Janette Seres-Mailo; Chris Hanstock; Peter Seres; Janisse Khudabux; François Bellavance; Glen Baker; Peter Allen; Philip Tibbo; Eric Hui; Jean-Michel Le Melledo
Journal:  Biol Psychiatry       Date:  2007-12-03       Impact factor: 13.382

9.  How does premenstrual dysphoric disorder relate to depression and anxiety disorders?

Authors:  Mikael Landén; Elias Eriksson
Journal:  Depress Anxiety       Date:  2003       Impact factor: 6.505

10.  The role of BDNF as a mediator of neuroplasticity in bipolar disorder.

Authors:  Iria Grande; Gabriel Rodrigo Fries; Mauricio Kunz; Flavio Kapczinski
Journal:  Psychiatry Investig       Date:  2010-12-15       Impact factor: 2.505

View more
  6 in total

1.  Therapeutic targets in major psychiatric disorders revisited.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-12       Impact factor: 5.270

2.  Serum Heat Shock Protein 70 Level in Children with Attention Deficiency Hyperactivity Disorder.

Authors:  Ahmet Özaslan; Esra Güney; Özlem Gülbahar; Dicle Büyüktaşkin Tunçtürk; Burak Arslan; Güner Melike Güveli Bozkurt
Journal:  Noro Psikiyatr Ars       Date:  2022-02-06       Impact factor: 1.339

3.  Brain-derived neurotrophic factor and mood in perimenopausal depression.

Authors:  Jessica A Harder; Raina N Fichorova; Akanksha Srivastava; Aleta Wiley; Katherine E Burdick; Joseph J Locascio; Hadine Joffe
Journal:  J Affect Disord       Date:  2021-12-23       Impact factor: 4.839

Review 4.  Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods.

Authors:  Claudia Barth; Arno Villringer; Julia Sacher
Journal:  Front Neurosci       Date:  2015-02-20       Impact factor: 4.677

5.  The Cerebellum and Premenstrual Dysphoric Disorder.

Authors:  Andrea J Rapkin; Steven M Berman; Edythe D London
Journal:  AIMS Neurosci       Date:  2014-07-30

Review 6.  Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders.

Authors:  Maria Grazia Perrone; Antonella Centonze; Morena Miciaccia; Savina Ferorelli; Antonio Scilimati
Journal:  Molecules       Date:  2020-11-18       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.